In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Bayer gets ex-US rights to anti-VEGF for eye diseases

Executive Summary

Wishing to capitalize on Bayer HealthCare's experience in specialized therapeutic categories, Regeneron Pharmaceuticals (has clinical-phase candidates in ophthalmology, oncology, and inflammation) has licensed the drug giant development and marketing rights outside the US to Phase I/II VEGF Trap-Eye for local treatment of eye diseases, including wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Contract
    • Co-Promotion
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register